34 results about "Meibomian gland dysfunction" patented technology

The invention relates to the technical field of cell biology, and particularly discloses an isolated culture method of primary meibomian gland epithelial cells, the obtained primary meibomian gland epithelial cells and application of the primary meibomian gland epithelial cells. The method comprises the following steps: efficiently and mildly digesting meibomian gland tissues by adopting a compound digestive juice consisting of I-type collagenase, dispersing enzyme and trypsin in a specific ratio; stopping digestion by using a serum-containing neutralizing solution and collecting cells; the method comprises the following steps: promoting cell attachment by using a serum-containing initial culture medium, and carrying out selective amplification by using a serum-free proliferation culture medium to finally obtain high-purity and high-activity primary meibomian gland epithelial cells. The method solves the problems of long digestion time, low cell yield, poor purity and the like in the traditional method. The obtained cell can be used for constructing a meibomian gland dysfunction model, screening drugs and researching lipid metabolism, and an important technical platform and a cell model are provided for research and treatment of related eye diseases.

The present invention relates to the use of the isoquinoline multifunctional ligand amino-7 triethoxy-4,5,6 oxo-1 dihydro-1,3 isobenzofuranyl-3)-1 methoxy-8 methyl-2 methylenedioxy-6,7 tetrahydro-2,3,4 isoquinoline or tritoqualine for the treatment of dry eye, meibomian gland dysfunction and lacrimal gland dysfunction.

The utility model discloses an auxiliary physiotherapy instrument for meibomian gland dysfunction, and relates to the technical field of treatment of meibomian gland related diseases in the ophthalmology department. Comprise two glasses frames forming the glasses, two glasses legs and a glasses beam between the two glasses frames, and non-light-transmitting lenses are arranged on the inner sides of the glasses frames; a face fitting type sealing structure is arranged on the side, facing the face, of the mirror frame, and the face fitting type sealing structure is fitted to the periphery of the eye socket of the face and forms a closed space covering the periphery of the eye socket of the face with the mirror frame and the non-light-transmitting lenses; an elastic contact ball is arranged on the side, facing the face, of the non-light-transmitting lens and used for elastically making contact with the tarsal parts of the eyes. A heating mechanism is arranged in the elastic contact ball and used for keeping the surface of the elastic contact ball at the temperature for hot compress of eyelids; an eye distance adaptive adjusting mechanism is arranged between the non-light-transmitting lens and the elastic contact ball and is used for supporting the elastic contact ball and adjusting the transverse position of the elastic contact ball on the inner side of the lens frame; and a vibratory massage driving mechanism is arranged on the glasses beam.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

A heated eye mask apparatus for therapeutic treatment of meibomian gland dysfunction, blepharitis, dry eye disease, and related ocular conditions. The apparatus comprises a body portion with adjustable straps and a pair of detachable eye covers releasably secured to the body portion via fastening mechanisms enabling positional adjustment. Each eye cover includes at least one heating element with multiple independently controllable heating zones, allowing targeted thermal therapy to specific periocular anatomical regions. The heating elements are powered by rechargeable batteries integrated within the body portion, providing cordless operation. Flexible tethers connect the eye covers to the body portion, providing mechanical retention and electrical connectivity. A control interface comprising user-actuatable buttons enables independent activation of heating zones. Alternative embodiments may include a steam generation system providing combined heat and moisture therapy. The adjustable configuration accommodates varying facial anatomies and enables customized treatment based on individual therapeutic requirements.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said compositions and methods comprise keratolytic agents, such as salicylic acid, selenium disulfide, or the like. Topical administration of said compositions to the eyelid margin or surrounding areas provides therapeutic benefit to patients suffering from meibomian gland dysfunction.

This invention discloses the application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome, relating to the field of biomedical technology. The application of LGK974 in the preparation of drugs for the prevention and / or treatment of dry eye syndrome. This invention is the first to discover the application of the Wnt-β-catenin pathway inhibitor LGK974 in the treatment of dry eye syndrome. LGK974, by inhibiting the Wnt-β-catenin pathway, can effectively protect meibomian gland acini and ducts, restoring normal lipid metabolism and secretion. In a NOD (Normally Ophthalmic Disorder) Sjögren's syndrome model, oral administration of 200-400 μg / kg / day of LGK974 significantly improved dry eye symptoms, including reduced corneal defects and increased tear secretion, alleviating morphological and functional damage to the meibomian glands. LGK974 provides a new targeted strategy for the treatment of dry eye syndrome, especially Sjögren's syndrome-related dry eye syndrome and meibomian gland dysfunction-related dry eye syndrome, and may become a potent and effective drug for the clinical treatment of dry eye in the future.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for the inhibition of CYP26B1. Aspects of the present disclosure also include methods of using the compounds in the treatment of diseases or conditions including, but not limited to, skin conditions, cancer, neurological conditions, heterotopic ossification (HO), progressive ossified fibrodysplasia (FOP), multiple osteochondroma, and ocular diseases or conditions, including meibomian gland dysfunction and dry eye disease.

According to the meibomian gland dysfunction treatment system and the control method, the equipment environment temperature and the host water outlet temperature are collected, a model is established in combination with the equipment heat exchange total thermal resistance, the actual temperature of the eye cup is accurately calculated, then the human body temperature and the man-machine heat exchange total thermal resistance are fused, and finally the steady-state temperature of the contact face of the eye cup and the human eyes is locked. Moreover, PID closed-loop control is adopted, temperature deviation in the heat exchange process of the equipment and the man-machine heat exchange process can be corrected in real time, a proportional link quickly responds to sudden fluctuation of the water flow temperature and the environment temperature, an integral link eliminates accumulated deviation such as continuous heat dissipation of a pipeline, a differential link prejudges the temperature change trend to avoid overshoot, and the heat exchange efficiency is improved. The temperature of the contact surface is always stabilized in a target range, the hot compress temperature is stabilized in a clinical effective interval, and the core target of treatment of lipid softening and gland opening expansion is realized.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

Described herein are compositions and methods for the treatment of meibomian gland dysfunction. Said methods are performed by administering said composition comprising a selenium disulfide and an anhydrous semi-solid base. The stable anhydrous composition are substantially free of selenium disulfide agglomerates.

This invention discloses a multi-dimensional quantitative assessment method and system combining meibomian gland morphology and function, belonging to the fields of ophthalmic diagnosis and artificial intelligence technology. It acquires color images of the eyelid margin, infrared images of the meibomian glands, and dynamic videos of gland expulsion upon pressure, inputting these into a dedicated AI analysis engine for processing. Employing an innovative anatomically guided backbone network and a meibomian gland region adaptive module, it achieves parallel automatic quantitative scoring across four dimensions: meibomian gland opening abnormality score, secretion characteristics score, expulsion capacity score, and morphological abnormality score based on gland segmentation loss rate. The four scores are summed to obtain a comprehensive total score, used for the graded diagnosis of meibomian gland dysfunction. By comparing changes in the patient's scores over time, it achieves macroscopic and microscopic evaluation of treatment efficacy. By integrating functional and morphological indicators into a unified automated quantitative system, it solves the problems of subjectivity and fragmentation in existing assessment methods, significantly improving the objectivity, comprehensiveness, and accuracy of diagnosis, and providing a reliable tool for individualized treatment and long-term management of MGD.

Blepharitis, an infection and inflammation of the edge of the eyelids, and meibomian gland dysfunction (MGD), blockage of tiny oil glands at the eye lid margin, are quite common, usually under diagnosed and underappreciated diseases. There are number of causes for blepharitis, including bacterial components such as Staphylococcus aureus, Staphylococcus epidermidis, Propionibacterium acnes and Corynebacteria sp., seborrhea or microscopic mites (Demodex). More than 50% of patients seeking ophthalmologic consultations have symptoms and signs indicating one of these entities. Another large number of patients remain undiagnosed or in early stages of disease that could be easily treated thus preventing long-term pain and suffering. MGD is in fact the leading cause of dry eye disease, a potentially preventable malady.

The utility model relates to meibomian gland dysfunction treatment technical field, especially for a kind of treatment device of meibomian gland dysfunction, including two groups of left-right symmetrical distribution's outer shell, the front end of the outer shell and along the rim place is wrapped with soft silica gel strip, the front end of the outer shell is connected with treatment eyecup, the inside of the treatment eyecup is evenly provided with steam outlet, the front end of the treatment eyecup outside is connected with sealing baffle, the outside of two groups the outer shell and towards the end of one end is connected with adjusting band, in the utility model, can carry out the sustained steam hot compress to eye, can be expanded meibomian gland opening by hot compress, improve secretion discharge, compared with towel, it is more convenient and fast, and can be adjusted according to eye interval, also can select single eye and double eye hot compress treatment, convenient to use, improve treatment efficiency.

This invention provides a treatment device for meibomian gland dysfunction, relating to the field of medical device technology. It addresses the technical problem that existing eyelid heating treatment devices can only achieve eyelid heating or require the administration of symptomatic medication before initiating heating treatment, failing to achieve simultaneous heating and medication action. The device includes a frame, shaped like an eyeglass frame, for the patient to wear; temples for fitting the frame around the patient's ears; a heating mechanism fixedly mounted on the frame, comprising a heating plate and heating cotton; the heating plate and heating cotton being fixedly mounted on the frame and conforming to the outer side of the patient's eyelid; and an atomizing mechanism for spraying atomized medication from the inside of the temples onto the patient's eyelid corresponding to the heating cotton. Through the eyeglass-frame-like frame, temples, and integrated heating and atomizing mechanisms, heating and medication are simultaneously administered, achieving integrated and synergistic treatment and improving efficacy.

1. The name of the design product: Eversion device. 2. The use of the design product: For the diagnosis of dry eye and meibomian gland dysfunction. 3. The design points of the design product: In shape. 4. The picture or photo that best indicates the design points: Design 1 perspective view 1. 5. Design 1 is designated as the basic design.

The invention relates to the field of pharmaceutical preparations, in particular to a preparation method and application of a stable nitroimidazole ophthalmic pharmaceutical composition. Specifically, the invention relates to an ophthalmic pharmaceutical composition, which comprises a nitroimidazole drug, a solubilizer, a stabilizer, a thickener, an osmotic pressure regulator and a pH regulator, and the stabilizer comprises a block polymer. The invention also relates to a preparation method of the ophthalmic pharmaceutical composition and application of the ophthalmic pharmaceutical composition in prevention / treatment of demodex blepharitis and meibomian gland dysfunction.

The invention discloses application of siRNA of silence Ier3 gene in preparation of medicine for preventing or treating meibomian gland dysfunction type dry eye, Ier3 gene expression is regulated and controlled through RNA interference technology, and meibomian gland dysfunction in plateau environment is relieved. The invention discovers that the expression of the early response gene Ier3 in hypoxia-induced meibomian gland dysfunction is up-regulated for the first time, and designs and synthesizes three specific siRNA sequences. Experiments adopt a low-pressure oxygen chamber to simulate an altitude of 5000 meters to construct a plateau mouse model, intervention is performed through an eye drop administration mode, and results show that Ier3 siRNA can significantly inhibit meibomian gland tissue Ier3 expression, prolong tear film rupture time and inhibit meibomian gland duct cell proliferation. The invention provides a precise treatment strategy based on the RNA interference technology, has the characteristics of strong targeting property, high gene silencing efficiency and small side effect, and provides a new intervention target and drug selection for the treatment of the plateau environment related meibomian gland dysfunction type dry eye.

The utility model provides a freezing device for constructing an atrophic meibomian gland dysfunction animal model, and belongs to the technical field of medicine. The problems that when an existing model is constructed, no matched damage device exists, damage to other parts is difficult to avoid when alkali damage and electrothermal firing are utilized, and operation is difficult are solved. Comprising a detachable nitrogen storage bottle and a bottle cap, the bottle cap is sequentially provided with a copper rod seat and a thermal insulation protection sleeve, a copper rod is arranged in the thermal insulation protection sleeve, one end of the copper rod extends out of the thermal insulation protection sleeve and is provided with a thin probe, the other end of the copper rod penetrates through the bottle cap and then extends into the nitrogen storage bottle, and a wire of a thermometer is in contact connection with the copper rod through a wire opening of the thermal insulation protection sleeve. The meibomian gland atrophy model can be used for constructing an atrophy meibomian gland dysfunction animal model, the blank in the field is filled up, the meibomian gland atrophy cells can be successfully damaged relative to alkali burn and electric heating guide wire injury, the atrophy of the meibomian glands is caused, the secretion function is reduced within a period of time, operation in a slit lamp is not needed, and the operation method is simple.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for the inhibition of CYP26B1. Aspects of the present disclosure also include methods of using the compounds in the treatment of diseases or conditions including, but not limited to, skin conditions, cancer, neurological conditions, heterotopic ossification (HO), progressive ossified fibrodysplasia (FOP), multiple osteochondroma, and ocular diseases or conditions, including meibomian gland dysfunction and dry eye disease.

Described herein are methods for the manufacture of compositions useful for the treatment of meibomian gland dysfunction. Said methods utilize rheological properties of petrolatum induced by a high shear mixing feature of the method. The products of the methods of manufacture described herein are stable anhydrous composition of selenium disulfide which are substantially free of selenium disulfide agglomerates and degradation products.

The invention relates to the field of medicines, in particular to fluoroalkanes, and a composition, a preparation method and application thereof. The invention has the following advantages: the invention provides fluoroalkane, and a composition, a preparation method and application thereof; the compound shown in the formula (I) or the pharmaceutically acceptable salt, the stereoisomer, the isotope variant, the solvate or the composition of the compound has the effects of stabilizing a tear film, dissolving meibolipid, dissolving earwax, inhibiting evaporation of water on the ocular surface, increasing the thickness of a tear film lipid layer, improving the spreadability of cornea, wetting the surface of the eye, preserving an isolated organ, improving the stability of the cornea and improving the quality of the eye. The pharmaceutical composition has the effects of improving the stability of a tear film, reducing the evaporation rate of tears, prolonging the rupture time of the tear film, treating meibomian fat abnormity, treating meibomian gland dysfunction, treating keratoconjunctivitis sicca, treating eye or ear related diseases such as xerophthalmia related diseases and / or delivering active pharmaceutical ingredients.

The invention discloses a meibomian gland dysfunction animal model construction method and an animal model, the construction method comprises the following steps: 1, animal anesthesia: adopting an inhalation anesthesia mode to carry out general anesthesia, and keeping eyelids in a slightly closed state; step 2, eye anesthesia: performing surface anesthesia on the left eye and / or the right eye of the animal to serve as a tested eye; step three, meibomian gland collagen crosslinking: applying riboflavin mixed liquid to the eyelid margin of the tested eye, then irradiating the eyelid margin with 365nm ultraviolet light to induce meibomian gland dysfunction, and placing for 7-10 days; and 4, repeating the operation process in the step 3 to obtain the meibomian gland dysfunction animal model. According to the method, the meibomian gland collagen crosslinking technology that the riboflavin and hydrogen peroxide mixed solution is smeared on the eyelid margin and the 365nm ultraviolet light irradiates the eyelid margin is utilized to induce meibomian gland dysfunction, the modeling time is short, and the operation is simple.

The present invention provides a Lotilaner-containing microemulsion eye drop, a preparation method therefor, and a use thereof in eye diseases such as demodex blepharitis, ocular rosacea, and meibomian gland dysfunction.

The application discloses application of a Piezo1 agonist in preparation of a medicine for treating meibomian gland dysfunction, and belongs to the technical field of biological medicines. The application first proposes Piezo1 as a brand-new medicine target for treating meibomian gland dysfunction. Experiments prove that the Piezo1 agonist can directly target the meibomian gland, effectively enhance the glycolysis level of cells, and then promote cell differentiation and lipid synthesis, so as to restore the gland function and treat meibomian gland dysfunction. The application provides a brand-new thought and strategy for research and development of a medicine for treating meibomian gland dysfunction, and has a wide clinical application prospect.

The utility model discloses a squeezer for meibomian gland dysfunction physical treatment, which comprises a squeezer main body, one side of one end of the squeezer main body is fixedly connected with an upper clamping plate, the other side of one end of the squeezer main body is fixedly connected with a lower clamping plate, one end of the upper clamping plate is provided with a limiting groove, and the surface of the limiting groove is in contact connection with a handheld structure. The squeezer for physical treatment of meibomian gland dysfunction is small in size and convenient to carry, through simple cooperation of the handheld structure and the squeezing structure, the squeezing roller squeezes meibomian glands, and the meibomian glands can be squeezed by the squeezing roller under the condition that damage to eyelid conjunctiva is reduced as much as possible. Most liquefied and accumulated lipid can be quickly and fully discharged from the blocked opening of the glandular duct, so that the opening of the meibomian gland is smooth, the operation difficulty is low, the meibomian gland is easy to master by a common patient, the risk that eyes are stimulated by far infrared light and the like is avoided, the use safety is higher, and the practicability is higher.

This invention provides a semi-fluorinated alkane eye drop containing loteranal and its preparation method, as well as its application in eye diseases such as Demodex blepharitis, ocular erythema acne, and meibomian gland dysfunction.

The invention relates to the technical field of medical detection, in particular to a tear film lipid layer thickness detection method and system, and the method comprises the following steps: collecting the interference image data of an ocular surface tear film through a special device, preprocessing the collected interference image data, carrying out the feature extraction of the preprocessed interference image, and obtaining the thickness of a tear film lipid layer. Extracting color, texture and shape features in the image, generating a feature vector, constructing and training a tear film lipid layer thickness prediction model by adopting a machine learning algorithm based on the feature vector, inputting interference image data of a to-be-detected tear film into the trained prediction model, calculating the thickness of the tear film lipid layer, and verifying a calculation result. The verified model and method are applied to clinical tear film lipid layer thickness detection to assist doctors in diagnosis and treatment of meibomian gland dysfunction. The tear film lipid layer thickness can be rapidly and accurately detected, manual operation errors are reduced, clinical diagnosis efficiency and accuracy are improved, and the method has remarkable clinical application value.